Trust in governance and the acceptance of genetically modified food in the Netherlands

This paper assumes that trust is a major issue in the interaction between government, citizens and societal organizations. The central question in this paper relates to the specific determinants of public trust. A survey study is reported (n = 1019) which focuses on the role of trust in the acceptance of genetically modified (GM) food. Our expectation was that three types of trust: “trust in governance,” “trust in government,” and “trust in NGOs” would be important predictors of the public acceptance of GM food. The data were collected in the summer of 2001 in the context of the formal Dutch public debate on GM food. The results indicate that 42 percent of the respondents do not trust developments in GM food. Only a third of the sample does trust the government with respect to GM food developments. Approximately 50 percent of the respondents express a high level of trust in nongovernmental organizations for this issue. The data further show that trust in governance seems to be an important constraint for the further development of GM food in the Netherlands. With higher levels of trust in governance people have a more positive attitude toward GM food, are more likely to accept it, and are more optimistic about technological developments

Many Labs 2: Investigating Variation in Replicability Across Samples and Settings

We conducted preregistered replications of 28 classic and contemporary published findings, with protocols that were peer reviewed in advance, to examine variation in effect magnitudes across samples and settings. Each protocol was administered to approximately half of 125 samples that comprised 15,305 participants from 36 countries and territories. Using the conventional criterion of statistical significance (p < .05), we found that 15 (54%) of the replications provided evidence of a statistically significant effect in the same direction as the original finding. With a strict significance criterion (p < .0001), 14 (50%) of the replications still provided such evidence, a reflection of the extremely highpowered design. Seven (25%) of the replications yielded effect sizes larger than the original ones, and 21 (75%) yielded effect sizes smaller than the original ones. The median comparable Cohen’s ds were 0.60 for the original findings and 0.15 for the replications. The effect sizes were small (< 0.20) in 16 of the replications (57%), and 9 effects (32%) were in the direction opposite the direction of the original effect. Across settings, the Q statistic indicated significant heterogeneity in 11 (39%) of the replication effects, and most of those were among the findings with the largest overall effect sizes; only 1 effect that was near zero in the aggregate showed significant heterogeneity according to this measure. Only 1 effect had a tau value greater than .20, an indication of moderate heterogeneity. Eight others had tau values near or slightly above .10, an indication of slight heterogeneity. Moderation tests indicated that very little heterogeneity was attributable to the order in which the tasks were performed or whether the tasks were administered in lab versus online. Exploratory comparisons revealed little heterogeneity between Western, educated, industrialized, rich, and democratic (WEIRD) cultures and less WEIRD cultures (i.e., cultures with relatively high and low WEIRDness scores, respectively). Cumulatively, variability in the observed effect sizes was attributable more to the effect being studied than to the sample or setting in which it was studied.UCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias Sociales::Instituto de Investigaciones Psicológicas (IIP

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Funder: NCI U24CA211006Abstract: The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) curated consensus somatic mutation calls using whole exome sequencing (WES) and whole genome sequencing (WGS), respectively. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2,658 cancers across 38 tumour types, we compare WES and WGS side-by-side from 746 TCGA samples, finding that ~80% of mutations overlap in covered exonic regions. We estimate that low variant allele fraction (VAF < 15%) and clonal heterogeneity contribute up to 68% of private WGS mutations and 71% of private WES mutations. We observe that ~30% of private WGS mutations trace to mutations identified by a single variant caller in WES consensus efforts. WGS captures both ~50% more variation in exonic regions and un-observed mutations in loci with variable GC-content. Together, our analysis highlights technological divergences between two reproducible somatic variant detection efforts

Wiens woord men gelooft diens brood men eet. De rol van publieksvertrouwen bij de acceptatie van genvoedsel.

Dit onderzoek gaat uit van de veronderstelling ook geopperd door de Commissie Toekomst Overheidscommunicatie, dat vertrouwen de komende jarenm een centraal thema zal zijn in de interactie tussen overheid en burger. In dit artikel wordt verslag gedaan van onderzoek naar die vertrouwensfactor.One eats the bread of those who we believe.The roles of public trust in the acceptance of gene foodThis paper is based on the assumption of the Committee on the Future of Government Communication that trust will be a major issue in the interaction between government and citizens A survey study is reported (n = 1019) which focuses on the role of trust in the acceptance of gene food. The data were collected in the summer of 1991 in the context of the DutchPublic debate on gene food. The results indicate that 42% of the respondents do not trust developments in gene food, and 46% does trust these developments. Most important determinants of public trust in gene food developments are the satisfaction with governmental and private sector communication, the respondent's age and gender, and the level of personal commitment to the issue of gene food. A small majority of the respondents does trust government with respect to gene food developments. Approximately three quarters of the respondents indicated to trust non-governmental organizations

Trust in governance and the acceptance of genetically modified food in the Netherlands

This paper assumes that trust is a major issue in the interaction between government, citizens and societal organizations. The central question in this paper relates to the specific determinants of public trust. A survey study is reported (n = 1019) which focuses on the role of trust in the acceptance of genetically modified (GM) food. Our expectation was that three types of trust: "trust in governance," "trust in government," and "trust in NGOs" would be important predictors of the public acceptance of GM food. The data were collected in the summer of 2001 in the context of the formal Dutch public debate on GM food. The results indicate that 42 percent of the respondents do not trust developments in GM food. Only a third of the sample does trust the government with respect to GM food developments. Approximately 50 percent of the respondents express a high level of trust in nongovernmental organizations for this issue. The data further show that trust in governance seems to be an important constraint for the further development of GM food in the Netherlands. With higher levels of trust in governance people have a more positive attitude toward GM food, are more likely to accept it, and are more optimistic about technological development

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

Background miR-122 is an important host factor for hepatitis C virus (HCV) replication. The aim of this study was to assess the safety and tolerability, pharmacokinetics, and antiviral effect of a single dose of RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated oligonucleotide that antagonises miR-122, in patients with chronic HCV infection with various genotypes. Methods In this randomised, double-blind, placebo-controlled, multicentre, phase 1B study, patients were randomly assigned to RG-101 or placebo (7: 1). We enrolled men and postmenopausal or hysterectomised women (aged 18-65 years) with chronic HCV genotype 1, 3, or 4 infection diagnosed at least 24 weeks before screening who were either treatment naive to or relapsed after interferon-alpha based therapy. Patients with co-infection (hepatitis B virus or HIV infection), evidence of decompensated liver disease, or a history of hepatocellular carcinoma were excluded. Randomisation was done by an independent, unblinded, statistician using the SAS procedure Proc Plan. The first cohort received one subcutaneous injection of 2 mg/kg RG-101 or placebo; the second cohort received one subcutaneous injection of 4 mg/kg or placebo. Patients were followed up for 8 weeks (all patients) and up to 76 weeks (patients with no viral rebound and excluding those who were randomised to the placebo group) after randomisation. The primary objective was safety and tolerability of RG-101. This trial was registered with EudraCT, number 2013-002978-49. Findings Between June 4, 2014, and Oct 27, 2014, we enrolled 32 patients with chronic HCV genotype 1 (n=16), 3 (n=10), or 4 (n=6) infections. In the first cohort, 14 patients were randomly assigned to receive 2 mg/kg RG-101 and two patients were randomly assigned to receive placebo, and in the second cohort, 14 patients were randomly assigned to receive 4 mg/kg RG-101 and two patients were randomly assigned to receive placebo. Overall, 26 of the 28 patients dosed with RG-101 reported at least one treatment-related adverse event. At week 4, the median viral load reduction from baseline was 4.42 (IQR 3.23-5.00) and 5.07 (4.19-5.35) log(10) IU/mL in patients dosed with 2 mg/kg RG-101 or 4 mg/kg RG-101. Three patients had undetectable HCV RNA levels 76 weeks after a single dose of RG-101. Viral rebound at or before week 12 was associated with the appearance of resistance associated substitutions in miR-122 binding regions in the 5' UTR of the HCV genome. Interpretation This study showed that one administration of 2 mg/kg or 4 mg/kg RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated anti-miR-122 oligonucleotide, was well tolerated and resulted in substantial viral load reduction in all treated patients within 4 weeks, and sustained virological response in three patients for 76 week